EP1390385A4 - Nucleic acid based modulation of female reproductive diseases and conditions - Google Patents

Nucleic acid based modulation of female reproductive diseases and conditions

Info

Publication number
EP1390385A4
EP1390385A4 EP02752028A EP02752028A EP1390385A4 EP 1390385 A4 EP1390385 A4 EP 1390385A4 EP 02752028 A EP02752028 A EP 02752028A EP 02752028 A EP02752028 A EP 02752028A EP 1390385 A4 EP1390385 A4 EP 1390385A4
Authority
EP
European Patent Office
Prior art keywords
conditions
nucleic acid
acid based
female reproductive
based modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02752028A
Other languages
German (de)
French (fr)
Other versions
EP1390385A2 (en
Inventor
Jaime Escobedo
James Mcswiggen
Pamela Pavco
Dan Stinchcomb
Jennifer Sandberg
Gilad Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Sirna Therapeutics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Sirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US870161 priority Critical
Priority to US87016101A priority
Priority to US33446101P priority
Priority to US334461P priority
Priority to US138674 priority
Priority to US10/138,674 priority patent/US7034009B2/en
Application filed by Novartis Vaccines and Diagnostics Inc, Sirna Therapeutics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Priority to PCT/US2002/017674 priority patent/WO2002096927A2/en
Priority claimed from EP06021209A external-priority patent/EP1767632A3/en
Publication of EP1390385A2 publication Critical patent/EP1390385A2/en
Publication of EP1390385A4 publication Critical patent/EP1390385A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/317Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/332Abasic residue
EP02752028A 1995-10-26 2002-05-29 Nucleic acid based modulation of female reproductive diseases and conditions Withdrawn EP1390385A4 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US870161 1997-06-06
US87016101A true 2001-05-29 2001-05-29
US33446101P true 2001-11-30 2001-11-30
US334461P 2001-11-30
US10/138,674 US7034009B2 (en) 1995-10-26 2002-05-03 Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US138674 2002-05-03
PCT/US2002/017674 WO2002096927A2 (en) 2001-05-29 2002-05-29 Ribozyme based treatment of female reproductive diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06021209A EP1767632A3 (en) 2001-05-29 2002-05-29 A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06021209A Division EP1767632A3 (en) 1995-10-26 2002-05-29 A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor

Publications (2)

Publication Number Publication Date
EP1390385A2 EP1390385A2 (en) 2004-02-25
EP1390385A4 true EP1390385A4 (en) 2004-11-24

Family

ID=27385212

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02752028A Withdrawn EP1390385A4 (en) 1995-10-26 2002-05-29 Nucleic acid based modulation of female reproductive diseases and conditions

Country Status (6)

Country Link
EP (1) EP1390385A4 (en)
JP (2) JP2005500025A (en)
AU (1) AU2002344237B8 (en)
CA (1) CA2448320A1 (en)
GB (1) GB0404461D0 (en)
WO (1) WO2002096927A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216335A1 (en) * 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7858769B2 (en) 2004-02-10 2010-12-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
FR2832154B1 (en) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotide inhibitors and their use for specifically repress a gene
AU2006203062B2 (en) * 2002-02-20 2009-03-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
MXPA04010282A (en) 2002-04-18 2005-08-18 Acuity Pharmaceuticals Inc Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye.
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
ES2439580T3 (en) * 2003-02-28 2014-01-23 The Johns Hopkins University T cell regulation
US7862816B2 (en) * 2003-03-12 2011-01-04 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004082626A2 (en) * 2003-03-18 2004-09-30 Ethicon, Inc. Aromatase inhibitor diagnosis and therapy
KR20060013428A (en) * 2003-06-06 2006-02-09 세네스코 테크놀로지스 인코포레이티드 Inhibition of apoptosis-specific eif-5a( eif-5a1 ) with antisense oligonucleotides and sirans as anti-inflammatory therapeutics
EP2338995A3 (en) 2003-08-28 2012-01-11 Novartis AG Interfering RNA duplex having blunt-ends and 3'-modifications
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
EP1687410A4 (en) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc Antisense oligonucleotides optimized for kidney targeting
AU2005213484A1 (en) * 2004-02-05 2005-08-25 Intradigm Corporation RNAi therapeutics for treatment of eye neovascularization diseases
US8980930B2 (en) * 2004-06-25 2015-03-17 The Johns Hopkins University Angiogenesis inhibitors
US20060115455A1 (en) * 2004-10-22 2006-06-01 Reed Kenneth C Therapeutic RNAi agents for treating psoriasis
EP1833966A2 (en) * 2004-12-14 2007-09-19 National Institute of Immunology Dnazymes for inhibition of japanese encephalitis virus replication
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
MX2007012766A (en) 2005-04-12 2008-10-01 Intradigm Corp Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases.
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US8093259B2 (en) * 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US20080268051A1 (en) 2007-04-30 2008-10-30 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
EP2361306A1 (en) 2008-12-04 2011-08-31 OPKO Ophthalmics, LLC Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
SG176939A1 (en) 2009-06-22 2012-01-30 Dmi Acquisition Corp Method for treatment of diseases
US20120263709A1 (en) 2009-09-10 2012-10-18 Schering Corporation Use of il-33 antagonists to treat fibrotic diseases
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
CN103068981A (en) 2010-07-28 2013-04-24 爱尔康研究有限公司 Sirna targeting VEGFA and methods for treatment in VIVO
EP3372684A1 (en) 2010-08-24 2018-09-12 Sirna Therapeutics, Inc. Single-stranded rnai agents containing an internal, non-nucleic acid spacer
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
CN104968350A (en) 2012-12-19 2015-10-07 安皮奥制药股份有限公司 Method for treatment of diseases
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
KR20160009575A (en) * 2013-05-22 2016-01-26 젠순 (상하이) 사이언스 앤드 테크놀로지 리미티드 Extended release of neuregulin for treating heart failure
CN103627709A (en) * 2013-12-06 2014-03-12 孙仑泉 Deoxyribozyme capable of suppressing genetic expression of vascular endothelial growth factor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015662A2 (en) * 1995-10-26 1997-05-01 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998306A1 (en) * 1997-07-24 2000-05-10 Inex Pharmaceuticals Corp. Liposomal compositions for the delivery of nucleic acid catalysts

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015662A2 (en) * 1995-10-26 1997-05-01 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ELBASHIR SAYDA M ET AL: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494 - 498, XP002206451, ISSN: 0028-0836 *
MCLAREN J: "Vascular endothelial growth factor and endometriotic angiogenesis", HUMAN REPRODUCTION UPDATE, vol. 6, no. 1, January 2000 (2000-01-01), pages 45 - 55, XP002298154, ISSN: 1355-4786 *
PARRISH S ET AL: "Functional anatomy of a dsRNA trigger: Differential requirement for the two trigger strands in RNA interference", MOLECULAR CELL, vol. 6, no. 5, November 2000 (2000-11-01), pages 1077 - 1087, XP002226298, ISSN: 1097-2765 *
See also references of WO02096927A3 *

Also Published As

Publication number Publication date
EP1390385A2 (en) 2004-02-25
AU2002344237B8 (en) 2008-11-06
AU2002344237B2 (en) 2008-10-23
CA2448320A1 (en) 2002-12-05
JP2005500025A (en) 2005-01-06
WO2002096927A2 (en) 2002-12-05
WO2002096927A3 (en) 2003-02-20
GB0404461D0 (en) 2004-03-31
JP2009000106A (en) 2009-01-08

Similar Documents

Publication Publication Date Title
AU2002332424A1 (en) Complexity management of genomic dna
AU2002313676A1 (en) Thermal cycling system and method of use
EP1402067A4 (en) HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE
EP1402053A4 (en) CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
IL161225D0 (en) Steerable segmented endoscope and method of insertion
PL371428A1 (en) Substituted indolizine-like compounds and methods of use
AU2002313683A1 (en) Nucleic acid amplification using nicking agents
IL157142D0 (en) Modified antibodies and methods of use
AU2001268363A1 (en) Treatment of B cell associated diseases
AU2002333700A1 (en) Impermanent biocompatible fastener
EP1283875A4 (en) Improved nucleic acid modifying enzymes
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
AU2002320185A1 (en) Biological activity of ak155
AU2002366306A1 (en) Animal breeding system and utilization of the system
AU5694701A (en) Formulations for neutralization of chemical and biological toxants
AU9458701A (en) Grip element and method of manufacture thereof
AU9096501A (en) Target activated nucleic acid biosensor and methods of using same
AU7510501A (en) Power mosfet and method of making the same
AU2002255543A1 (en) Method of controlling body temperature
AU4657500A (en) Locked nucleic acid hybrids and methods of use
AU2002236830A1 (en) Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
AU2002349606A1 (en) Processes for the preparation of glutamic acid compounds and intermediates thereof and novel intermediates used in the processes
AU2002338329A1 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
AU2002324505A1 (en) System for conversion of bracelet into necklace
AU2002354577A1 (en) Nucleotide compositions comprising photocleavable markers and methods of preparation thereof

Legal Events

Date Code Title Description
AX Request for extension of the european patent to

Countries concerned: ALLTLVMKROSI

17P Request for examination filed

Effective date: 20031125

AK Designated contracting states:

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIN1 Inventor (correction)

Inventor name: PAVCO, PAMELA

Inventor name: MCSWIGGEN, JAMES

Inventor name: GORDON, GILAD

Inventor name: STINCHCOMB, DAN

Inventor name: ESCOBEDO, JAIME

Inventor name: SANDBERG, JENNIFER

A4 Supplementary search report

Effective date: 20041008

17Q First examination report

Effective date: 20050207

18W Withdrawn

Effective date: 20061102